BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ward JW, Hinman AR. What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats. Gastroenterology. 2019;156:297-310. [PMID: 30391470 DOI: 10.1053/j.gastro.2018.10.048] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Kwong AJ, Kwo PY. Editorial: glecaprevir/pibrentasvir for the treatment of hepatitis C virus-do baseline resistance-associated substitutions matter? Aliment Pharmacol Ther 2020;51:739-40. [PMID: 32162374 DOI: 10.1111/apt.15656] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Xu D, Tian Y, Xia Q, Ke B. The cGAS-STING Pathway: Novel Perspectives in Liver Diseases. Front Immunol 2021;12:682736. [PMID: 33995425 DOI: 10.3389/fimmu.2021.682736] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Vyhmeister R, Enestvedt CK. The Changing Liver Transplant Recipient: From Hepatitis C to Nonalcoholic Steatohepatitis and Alcohol. Clin Liver Dis 2021;25:137-55. [PMID: 33978575 DOI: 10.1016/j.cld.2020.08.012] [Reference Citation Analysis]
4 Ward JW, Wiktor SZ, Cooke GS. Launch of the Coalition for Global Hepatitis Elimination: a recommendation of the Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol 2020;5:8-10. [PMID: 31669194 DOI: 10.1016/S2468-1253(19)30319-X] [Reference Citation Analysis]
5 Liu Z, Shi O, Zhang T, Jin L, Chen X. Disease burden of viral hepatitis A, B, C and E: A systematic analysis. J Viral Hepat 2020;27:1284-96. [PMID: 32741034 DOI: 10.1111/jvh.13371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Alter HJ, Chisari FV. Is Elimination of Hepatitis B and C a Pipe Dream or Reality? Gastroenterology 2019;156:294-6. [PMID: 30593764 DOI: 10.1053/j.gastro.2018.12.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Balagopal A, Thio CL. When viruses collide: hepatitis B virus reactivation after hepatitis C treatment. J Clin Invest 2020;130:2823-6. [PMID: 32420916 DOI: 10.1172/JCI137477] [Reference Citation Analysis]
8 Dash S, Aydin Y, Moroz K. Chaperone-Mediated Autophagy in the Liver: Good or Bad? Cells 2019;8:E1308. [PMID: 31652893 DOI: 10.3390/cells8111308] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
9 Koc ÖM, Hens N, Bielen R, Van Damme P, Robaeys G. Hepatitis B virus prevalence and risk factors in hard-to-reach Turkish population living in Belgium: A protocol for screening. Medicine (Baltimore) 2019;98:e15412. [PMID: 31045797 DOI: 10.1097/MD.0000000000015412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Qiu J, Zhou Q, Zhang Y, Guan M, Li X, Zou Y, Huang X, Zhao Y, Chen W, Gu X. Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents. Eur J Med Chem 2020;205:112581. [PMID: 32791397 DOI: 10.1016/j.ejmech.2020.112581] [Reference Citation Analysis]
11 Gonzalez HC, Gordon SC. Hepatitis C: Does Successful Treatment Alter the Natural History and Quality of Life? Gastroenterol Clin North Am 2020;49:301-14. [PMID: 32389364 DOI: 10.1016/j.gtc.2020.01.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Koc Ö, Van Damme P, Busschots D, Bielen R, Forier A, Nevens F, Robaeys G. Acute hepatitis B notification rates in Flanders, Belgium, 2009 to 2017. Euro Surveill 2019;24. [PMID: 31362809 DOI: 10.2807/1560-7917.ES.2019.24.30.1900064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Miyakawa Y, Otsuka M, Sekiba K, Funato K, Koike K. Humanized virus-suppressing factor inhibits hepatitis B virus infection by targeting viral cell entry. Heliyon 2021;7:e07586. [PMID: 34345745 DOI: 10.1016/j.heliyon.2021.e07586] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Brunner N, Bruggmann P. Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination. J Prev Med Public Health 2021;54:251-8. [PMID: 34370938 DOI: 10.3961/jpmph.21.151] [Reference Citation Analysis]
15 Zhang W, Aryan M, Qian S, Cabrera R, Liu X. A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. Gastroenterology Res 2021;14:139-56. [PMID: 34267829 DOI: 10.14740/gr1405] [Reference Citation Analysis]
16 Enomoto H, Ueno Y, Hiasa Y, Nishikawa H, Hige S, Takikawa Y, Taniai M, Ishikawa T, Yasui K, Takaki A, Takaguchi K, Ido A, Kurosaki M, Kanto T, Nishiguchi S; Japan Etiology of Liver Cirrhosis Study Group in the 54th Annual Meeting of JSH. Transition in the etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol 2020;55:353-62. [PMID: 31768801 DOI: 10.1007/s00535-019-01645-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
17 Ma CD, Imamura M, Talley DC, Rolt A, Xu X, Wang AQ, Le D, Uchida T, Osawa M, Teraoka Y, Li K, Hu X, Park SB, Chalasani N, Irvin PH, Dulcey AE, Southall N, Marugan JJ, Hu Z, Chayama K, Frankowski KJ, Liang TJ. Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion. Nat Microbiol 2020;5:1532-41. [PMID: 32868923 DOI: 10.1038/s41564-020-0781-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Cotter TG, Jensen DM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther 2019;13:2565-77. [PMID: 31534310 DOI: 10.2147/DDDT.S172512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
19 Rolt A, Talley DC, Park SB, Hu Z, Dulcey A, Ma C, Irvin P, Leek M, Wang AQ, Stachulski AV, Xu X, Southall N, Ferrer M, Liang TJ, Marugan JJ. Discovery and Optimization of a 4-Aminopiperidine Scaffold for Inhibition of Hepatitis C Virus Assembly. J Med Chem 2021;64:9431-43. [PMID: 34184537 DOI: 10.1021/acs.jmedchem.1c00696] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Otoguro T, Tanaka T, Kasai H, Kobayashi N, Yamashita A, Fukuhara T, Ryo A, Fukai M, Taketomi A, Matsuura Y, Moriishi K. Establishment of a Cell Culture Model Permissive for Infection by Hepatitis B and C Viruses. Hepatol Commun 2021;5:634-49. [PMID: 33860122 DOI: 10.1002/hep4.1653] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Mangia A, Cotugno R, Cocomazzi G, Squillante MM, Piazzolla V. Hepatitis C virus micro-elimination: Where do we stand? World J Gastroenterol 2021; 27(16): 1728-1737 [PMID: 33967553 DOI: 10.3748/wjg.v27.i16.1728] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Alqahtani SA, Colombo M. Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma. Cells 2021;10:3091. [PMID: 34831314 DOI: 10.3390/cells10113091] [Reference Citation Analysis]
23 Tian J, Hu D. LncRNA SLC16A1-AS1 is upregulated in hepatocellular carcinoma and predicts poor survival. Clin Res Hepatol Gastroenterol 2021;45:101490. [PMID: 33744723 DOI: 10.1016/j.clinre.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Liu Y, Zhao ZH, Lv XQ, Tang YW, Cao M, Xiang Q, Wu Y, Zhang HT, Lai GQ. Precise analysis of the effect of basal core promoter/precore mutations on the main phenotype of chronic hepatitis B in mouse models. J Med Virol 2020. [PMID: 32427358 DOI: 10.1002/jmv.26025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Kamiya N, Sugimoto T, Abe-Chayama H, Akiyama R, Tsuboi Y, Mogami A, Imamura M, Hayes CN, Chayama K. Untying relaxed circular DNA of hepatitis B virus by polymerase reaction provides a new option for accurate quantification and visualization of covalently closed circular DNA. J Gen Virol 2022;103. [PMID: 35130138 DOI: 10.1099/jgv.0.001591] [Reference Citation Analysis]
26 Perfect C, Jhaveri R. Hepatitis C Virus in Children: Trying to Overcome the Domestic and Global Challenges of Cases and Cost. J Pediatric Infect Dis Soc 2021;10:71-4. [PMID: 31616918 DOI: 10.1093/jpids/piz069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Paccoud O, Surgers L, Lacombe K. [Hepatitis B virus infection: Natural history, clinical manifestations and therapeutic approach]. Rev Med Interne 2019;40:590-8. [PMID: 30982550 DOI: 10.1016/j.revmed.2019.03.333] [Reference Citation Analysis]
28 Yakovchenko V, Morgan TR, Chinman MJ, Powell BJ, Gonzalez R, Park A, Malone PS, Chartier M, Ross D, Rogal SS. Mapping the road to elimination: a 5-year evaluation of implementation strategies associated with hepatitis C treatment in the veterans health administration. BMC Health Serv Res 2021;21:1348. [PMID: 34922538 DOI: 10.1186/s12913-021-07312-4] [Reference Citation Analysis]
29 Higuera-de la Tijera F, Servín-Caamaño A, Servín-Abad L. Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination. World J Gastroenterol 2021; 27(26): 4004-4017 [PMID: 34326610 DOI: 10.3748/wjg.v27.i26.4004] [Reference Citation Analysis]
30 Song Y, Li M, Wang Y, Zhang H, Wei L, Xu W. E3 ubiquitin ligase TRIM21 restricts hepatitis B virus replication by targeting HBx for proteasomal degradation. Antiviral Res 2021;192:105107. [PMID: 34097931 DOI: 10.1016/j.antiviral.2021.105107] [Reference Citation Analysis]
31 Boni C, Barili V, Acerbi G, Rossi M, Vecchi A, Laccabue D, Penna A, Missale G, Ferrari C, Fisicaro P. HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications. Int J Mol Sci 2019;20:E2754. [PMID: 31195619 DOI: 10.3390/ijms20112754] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
32 Gersten O, Barbieri M. Evaluation of the Cancer Transition Theory in the US, Select European Nations, and Japan by Investigating Mortality of Infectious- and Noninfectious-Related Cancers, 1950-2018. JAMA Netw Open 2021;4:e215322. [PMID: 33843999 DOI: 10.1001/jamanetworkopen.2021.5322] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Koc ÖM, Kremer C, Hens N, Bielen R, Busschots D, Van Damme P, Robaeys G. Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium. PLoS One 2020;15:e0234740. [PMID: 32716949 DOI: 10.1371/journal.pone.0234740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Chen CY, Fang JY, Chen CC, Chuang WY, Leu YL, Ueng SH, Wei LS, Cheng SF, Hsueh C, Wang TH. 2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression. Front Oncol 2020;10:1319. [PMID: 32850418 DOI: 10.3389/fonc.2020.01319] [Reference Citation Analysis]
35 Meringer H, Shibolet O, Deutsch L. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm? World J Gastroenterol 2019; 25(29): 3929-3940 [PMID: 31413528 DOI: 10.3748/wjg.v25.i29.3929] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
36 Fisicaro P, Barili V, Rossi M, Montali I, Vecchi A, Acerbi G, Laccabue D, Zecca A, Penna A, Missale G, Ferrari C, Boni C. Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches. Front Immunol. 2020;11:849. [PMID: 32477347 DOI: 10.3389/fimmu.2020.00849] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
37 Zeng QL, Zhang HX, Zhang JY, Huang S, Li WZ, Li GM, Pan YJ, Feng YH, Li ZQ, Zhang GF, Xu JH, Lin WB, Xu GH, Liu N, Zhang GQ, Li GT, Li W, Zeng YL, Song N, Wang M, Zhang DW, Chen ZM, Cui GL, Li J, Lv J, Liu YM, Liang HX, Sun CY, Zhou YH, Yu ZJ, Wang FS. Tenofovir Alafenamide for Pregnant Chinese Women with Active Chronic Hepatitis B: A Multicenter Prospective Study. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01306-9. [PMID: 34902570 DOI: 10.1016/j.cgh.2021.12.012] [Reference Citation Analysis]
38 de Andrade AA, Silva ÁMDCE, Carneiro MADS, Teles SA, Martins RMB. Hepatitis C prevalence among men who have sex with men in Central Brazil. Braz J Infect Dis 2019;23:271-3. [PMID: 31344354 DOI: 10.1016/j.bjid.2019.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Verma M, Chu JN, Salama JAF, Faiz MT, Eweje F, Gwynne D, Lopes A, Hess K, Soares V, Steiger C, McManus R, Koeppen R, Hua T, Hayward A, Collins J, Tamang SM, Ishida K, Miller JB, Katz S, Slocum AH, Sulkowski MS, Thomas DL, Langer R, Traverso G. Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine. Proc Natl Acad Sci U S A 2020;117:11987-94. [PMID: 32424082 DOI: 10.1073/pnas.2004746117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
40 Hinman AR, Orenstein WA. Elimination of cervical cancer: Lessons learned from polio and earlier eradication programs. Prev Med 2021;144:106325. [PMID: 33678231 DOI: 10.1016/j.ypmed.2020.106325] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Lu Y, Yang X, Zhang L. Domain I of hepatitis C virus NS5A associates with ACBD3 in a genotype-dependent manner. Microbiol Immunol 2020;64:574-7. [PMID: 32108375 DOI: 10.1111/1348-0421.12784] [Reference Citation Analysis]
42 Marcellin F, Jaquet A, Lazarus JV, Molina P, Carrieri P. Alcohol Use Disorder and Hepatitis C Prevention and Care in People Who Inject Drugs: The State of Play. Semin Liver Dis 2021;41:109-16. [PMID: 32851613 DOI: 10.1055/s-0040-1716343] [Reference Citation Analysis]